Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer

被引:28
作者
Xu, Ting [1 ]
Liao, Zhongxing [1 ]
O'Reilly, Michael S. [1 ]
Levy, Lawrence B. [1 ]
Welsh, James W. [1 ]
Wang, Li-E. [2 ]
Lin, Steven H. [1 ]
Komaki, Ritsuko [1 ]
Liu, Zhensheng [3 ]
Wei, Qingyi [3 ]
Gomez, Daniel R. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA
[3] Duke Canc Inst, Dept Med, Durham, NC USA
关键词
Radio(chemo)therapy; miRNA; Radiation esophagitis; NSCLC; MICRORNAS; EXPRESSION; INDUCTION; GROWTH; RISK; GENE;
D O I
10.1016/j.radonc.2014.11.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: MicroRNAs (miRNAs) are small, highly conserved non-coding RNAs that regulate many biological processes. We sought to investigate whether three serum miRNAs related to immunity or inflammation were associated with esophagitis induced by chemoradiation therapy (CRT) for non-small cell lung cancer (NSCLC). Material and methods: We measured serum miR-155, miR-221 and miR-21, before and during week 1-2 of CRT for 101 NSCLC patients by real-time PCR. Associations between miRNA and severe radiation-induced esophageal toxicity (RIET) were analyzed by logistic regression. Results: We found that patients with stage IIIB-IV disease, higher mean esophagus dose or esophageal V-50 had higher rates of severe RIET. Furthermore, high levels of miR-155 and miR-221 at week 1-2 of CRT were also risk factors for severe RIET (miR-155: OR = 1.53, 95% CI: 1.04-2.25, P = 0.03; miR-221: OR= 2.07, 95% CI: 1.17-3.64, P = 0.012). In addition, the fold change of miR-221 was also predictive of severe RIET (OR = 1.18, 95% CI: 1.02-1.37, P = 0.026). However, pretreatment miRNAs was not predictive of severe RIET. Conclusions: High serum miR-155 and miR-221 during the first 2 weeks of CRT were associated with the development of severe RIET, suggesting that these miRNAs may be useful as an early surrogate for this form of toxicity. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:379 / 384
页数:6
相关论文
共 50 条
  • [31] miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential
    Yan, Hang
    Tang, Shengjie
    Tang, Shoujun
    Zhang, Jun
    Guo, Haiyang
    Qin, Chao
    Hu, Haiyang
    Zhong, Chuan
    Yang, Li
    Zhu, Yunhe
    Zhou, Haining
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] A molecular and staging model predicts survival in patients with resected non-small cell lung cancer
    Liu, Lei
    Shi, Minxin
    Wang, Zhiwei
    Lu, Haimin
    Li, Chang
    Tao, Yu
    Chen, Xiaoyan
    Zhao, Jun
    BMC CANCER, 2018, 18
  • [33] The role of inflammatory and remodelling biomarkers in patients with non-small cell lung cancer
    Omer, Hemn abdalla
    Janson, Christer
    Amin, Kawa
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 48 (04) : 330 - 337
  • [34] A new mouse avatar model of non-small cell lung cancer
    Russo, Maria Veronica
    Faversani, Alice
    Gatti, Stefano
    Ricca, Dario
    Del Gobbo, Alessandro
    Ferrero, Stefano
    Palleschi, Alessandro
    Vaira, Valentina
    Bosari, Silvano
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [35] Association of HIF1-α gene polymorphisms with advanced non-small cell lung cancer prognosis in patients receiving radiation therapy
    Zhang, Yan
    Wang, Jian
    Li, Zhanzhan
    AGING-US, 2021, 13 (05): : 6849 - 6865
  • [36] Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark
    Dalvi, Tapashi
    Norgaard, Mette
    Fryzek, Jon P.
    Movva, Naimisha
    Pedersen, Lars
    Hansen, Hanh Pham
    Walker, Jill
    Midha, Anita
    Shire, Norah
    Boothman, Anne-Marie
    Rigas, James
    Mellemgaard, Anders
    Rasmussen, Torben R.
    Hamilton-Dutoit, Stephen
    Cronin-Fenton, Deirdre
    PLOS ONE, 2023, 18 (04):
  • [37] Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients
    Hocker, James R.
    Deb, Subrato J.
    Li, Min
    Lerner, Megan R.
    Lightfoot, Stan A.
    Quillet, Aurelien A.
    Hanas, R. Jane
    Reinersman, Matthew
    Thompson, Jess L.
    Vu, Nicole T.
    Kupiec, Thomas C.
    Brackett, Daniel J.
    Peyton, Marvin D.
    Dubinett, Stephen M.
    Burkhart, HaroldM.
    Postier, Russell G.
    Hanas, Jay S.
    CANCER INVESTIGATION, 2017, 35 (09) : 573 - 585
  • [38] Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents
    Wang, Yan
    Hu, Yuanyuan
    Wang, Ting
    Che, Guowei
    Li, Lu
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [39] Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer
    Gu, Xiaobin
    Tian, Tian
    Zhang, Bo
    Liu, Yang
    Yuan, Chao
    Shao, Lijuan
    Guo, Yajun
    Fan, Kexing
    TUMOR BIOLOGY, 2015, 36 (04) : 2651 - 2656
  • [40] The Impact of Inflammatory Serum Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
    Cipriano, E.
    Magalhaes, H.
    Estevinho, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S255 - S255